Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Addex Therapeutics (ADXN) FCF Margin (2019 - 2024)

Addex Therapeutics' FCF Margin history spans 6 years, with the latest figure at 354689630316.51% for Q4 2024.

  • On a quarterly basis, FCF Margin rose 34989087175466.0% to 354689630316.51% in Q4 2024 year-over-year; TTM through Dec 2025 was 56507829.85%, a 9071721733.0% increase, with the full-year FY2025 number at 7243.82%, down 591375.0% from a year prior.
  • FCF Margin came in at 354689630316.51% for Q4 2024, up from 9937390732.37% in the prior quarter.
  • The five-year high for FCF Margin was 354689630316.51% in Q4 2024, with the low at 9937390732.37% in Q3 2024.
  • Historically, FCF Margin has averaged 17451097397.87% across 5 years, with a median of 653.42% in 2021.
  • Peak annual rise in FCF Margin hit 2000000000bps in 2024, while the deepest fall reached 2000000000bps in 2024.
  • Year by year, FCF Margin stood at 34.83% in 2020, then crashed by -2255bps to 750.59% in 2021, then skyrocketed by 31bps to 518.71% in 2022, then soared by 925140749bps to 4798758561.85% in 2023, then soared by 7291bps to 354689630316.51% in 2024.
  • Business Quant data shows FCF Margin for ADXN at 354689630316.51% in Q4 2024, 9937390732.37% in Q3 2024, and 1908151346.6% in Q2 2024.